Ovarian Cancer Diagnostics Market

Global Ovarian Cancer Diagnostics Market Size, Trends, and Analysis - Forecasts to 2026 By Diagnosis (Imaging [Ultrasound, CT scan, MRI Scan, PET Scan, Others], Blood Test [CA125, HER2, BRCA, CEA, ER & PR, KRAS Mutation, Others], Biopsy, Others), By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell, Others), By End-Use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Category Healthcare

Format

This report was recently updated on April 30 2024 with the latest and most recent market numbers

Ovarian Cancer Diagnostics Market: Insights

The global ovarian cancer diagnostics market is projected to grow from USD 25.0 billion in 2021 to USD 36.5 billion by 2026 at a CAGR value of 7.5%. Factors like the rising prevalence of ovarian cancer, rising consumption of unhealthy foods, increasing chronic disorders related to the reproductive organ, technological advancements in cancer diagnosis, rising awareness regarding pre-disease diagnosis and other health concerns, non-invasive nature of the technique to detect the tumor will help the market grow rapidly from 2021 to 2026.

Other factors such as new product developments and product launch strategies by top market players, easy availability of diagnostic medical devices in developing regions, rising geriatric women population, increasing emphasis on early diagnosis and treatment, rising funding for research activities to launch non-invasive treatment therapies, increasing studies on novel approaches in the ovarian cancer treatment are expected to increase demand for the ovarian cancer diagnostics market.

Ovarian cancer is a subtle disease. While the cautions are the same, the most prevalent type of ovarian cancer starts in the aphelion cells, a type of cell that makes up the ovary surface tissue. To treat ovarian cancer effectively, doctors must first confirm the diagnosis and determine the illness's stage or extent. This requires a procedure known as surgical staging, in which a surgeon examines the pelvic and abdominal areas carefully.

Ovarian cancer is more common in women over the age of 50. About 80% of the ovarian cancers occur in women who are above the age of 50, and it usually happens after menopause. It can, however, happen to women, especially if they have a family history of breast or ovarian cancer in two or more close relatives. There are over a range of symptoms women present with when they are diagnosed with ovarian cancer.

Ovarian Cancer Diagnostics Market: By Cancer Type

Based on the type of cancer segment, the market is segregated into three categories include epithelial tumor, germ cell tumor, and stromal cell. The location of growing malignant cells determines the kind of ovarian cancer. In 2020, epithelial tumors was analyzed to be the frontrunner in the market. Serous, endometrioid, mucinous, and clear cell epithelial tumours are all numerous types of epithelial tumours. After the tumor has spread to the peritoneal cavity, the majority of epithelial cell carcinoma patients are diagnosed. Hence, with the rising prevalence of epithelial tumors, the segment is ought to be the largest growing segment.

Ovarian Cancer Diagnostics Market: By Diagnosis

According to the diagnosis segment, the four categories include imaging, blood test, biopsy and others. The imaging category is expected to hold the largest share in the market during the forecast period of 2021-2026. In the imaging segment, the CT scan segment will be constituting to the largest share in the market. CT scans, or computed tomography scans, create cross-sectional images of the body using computers and rotating X-ray devices. It has acquired the largest share in the market due to the factors like shorter study time, increasing importance of early diagnosis and cancer staging, rising awareness regarding the availability of the device, high-quality images, availability of a diversity of applications, non-invasive in nature, the working principal of CT is based on the advanced imaging technologies, higher accuracy than other imaging machines, non-invasive diagnostic therapy, cost-efficient, and reduces the need for exploratory surgeries.

However, the blood test segment will grow the fastest in the market due to the rapidly expanding healthcare industry, increasing patient awareness regarding blood screening, and improved healthcare management system in developing regions.

Ovarian Cancer Diagnostics Market: By End Use

According to the end-use analysis, the four segments are hospital laboratories, cancer diagnostic centers, and research institutes. In 2020, the hospital laboratories segment was analyzed to be largest shareholder in the market mainly due to the increasing patient inflow for cancer diagnostics in hospitals, availability of personalized care, quality care treatment, greater flexibility, growing need for comfort and convenience among the patents.

However, the research institutes will be growing the fastest due to factors like increasing funding schemes for cancer research worldwide, the rising potential of imaging tools in treatment therapies, rising customer centric treatment system, and rising product development in the field of ovarian cancer diagnostics.

asia pacific ovarian cancer diagnostics market

Ovarian Cancer Diagnostics Market: By Region

As per the geographical analysis, the market of ovarian cancer diagnostics can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central & South America.

The market of North America will be dominant from 2021 to 2026 due to the presence of a large number of key market players and industries, robust healthcare infrastructure, increasing investments in advanced imaging machines, quick adoption of latest technologies and devices, increasing awareness about ovarian cancer, strong commercial performances of the gynecologic diagnostics, abundance of qualified healthcare providers, and the continuous launch of improved products.

However, the Asia Pacific region will grow the fastest due to the rising geriatric women population, improvements in gynecology care facilities, rising occurrence of ovarian cancer, rising disposable income, increasing healthcare expenditure, and growing patient awareness. The other factor contributing to the growth of the APAC market is the rising medical tourism industry.

Ovarian Cancer Diagnostics Market: Share & Competitor Analysis

F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca plc., Siemens Healthcare GmbH, Quest Diagnostics Incorporated., Thermo Fisher Scientific, Bio-Rad Technologies Inc., Abbott, among others, are the key players competing in the ovarian cancer diagnostics market.

Please note: This is not an exhaustive list of companies profiled in the report.

In July 2020, Roche, conducted a research on Tecentriq (atezolizumab) to understand its association with Avastin (bevacizumab). The aim of the research was to analyze the progression-free survival (PFS) in women with clinically diagnosed advanced-stage ovarian cancer and its connection with Tecentriq and Avastin.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Global Ovarian Cancer Diagnostics Industry Overview, 2019-2026

2.1.1 Industry Overview

2.1.2 Diagnosis Overview

2.1.3 Cancer Type Overview

2.1.4 End-Use Overview

2.1.5 Regional Overview

Chapter 3 Global Ovarian Cancer Diagnostics Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2019-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 The rising prevalence of ovarian cancer

3.3.2 Industry Challenges

3.3.2.1 The high cost associated with the treatment and diagnosis in developing countries

3.4 Prospective Growth Scenario

3.4.1 Diagnosis Growth Scenario

3.4.2 Cancer Type Growth Scenario

3.4.3 End-Use Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Global Ovarian Cancer Diagnostics Market, By Diagnosis

4.1 Diagnosis Outlook

4.2 Imaging Techniques

4.2.1 Market Size, By Region, 2019-2026 (USD Billion)

4.3 Blood Test

4.3.1 Market Size, By Region, 2019-2026 (USD Billion)

4.4 Biopsy

4.4.1 Market Size, By Region, 2019-2026 (USD Billion)

Chapter 5 Global Ovarian Cancer Diagnostics Market, By Cancer Type

5.1 Cancer Type Outlook

5.2 Epithelial Tumor

5.2.1 Market Size, By Region, 2019-2026 (USD Billion)

5.3 Germ Cell Tumor

5.3.1 Market Size, By Region, 2019-2026 (USD Billion)

5.4 Stromal Cell

5.4.1 Market Size, By Region, 2019-2026 (USD Billion)

5.5 Others

5.5.1 Market Size, By Region, 2019-2026 (USD Billion)

Chapter 6 Ovarian Cancer Diagnostics Market, By End-Use

6.1 End-Use Outlook

6.2 Hospital Laboratories

6.2.1 Market size, By Region, 2019-2026 (USD Billion)

6.3 Cancer Diagnostic Centers

6.3.1 Market size, By Region, 2019-2026 (USD Billion)

6.4 Research Institutes

6.4.1 Market size, By Region, 2019-2026 (USD Billion)

6.5 Others

6.5.1 Market size, By Region, 2019-2026 (USD Billion)

Chapter 7 Global Ovarian Cancer Diagnostics Market, By Region

7.1 Regional outlook

7.2 North America

7.2.1 Market Size, By Country 2019-2026 (USD Billion)

7.2.2 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.2.3 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.2.4 Market Size, By End-Use, 2019-2026 (USD Billion)

7.2.5 U.S.

7.2.5.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.2.5.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.2.5.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.2.6 Canada

7.2.6.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.2.6.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.2.6.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3 Europe

7.3.1 Market Size, By Country 2019-2026 (USD Billion)

7.3.2 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.3.3 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.3.4 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3.5 Germany

7.2.5.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.2.5.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.2.5.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3.6 UK

7.3.6.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.3.6.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.3.6.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3.7 France

7.3.7.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.3.7.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.3.7.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3.8 Italy

7.3.8.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.3.8.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.3.8.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3.9 Spain

7.3.9.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.3.9.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.3.9.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.3.10 Russia

7.3.10.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.3.10.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.3.10.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.4 Asia Pacific

7.4.1 Market Size, By Country 2019-2026 (USD Billion)

7.4.2 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.4.3 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.4.4 Market Size, By End-Use, 2019-2026 (USD Billion)

7.4.5 China

7.4.5.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.4.5.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.4.5.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.4.6 India

7.4.6.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.4.6.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.4.6.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.4.7 Japan

7.4.7.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.4.7.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.4.7.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.4.8 Australia

7.4.8.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.4.8.2 Market size, By Cancer Type, 2019-2026 (USD Billion)

7.4.8.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.4.9 South Korea

7.4.9.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.4.9.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.4.9.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.5 Latin America

7.5.1 Market Size, By Country 2019-2026 (USD Billion)

7.5.2 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.5.3 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.5.4 Market Size, By End-Use, 2019-2026 (USD Billion)

7.5.5 Brazil

7.5.5.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.5.5.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.5.5.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.5.6 Mexico

7.5.6.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.5.6.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.5.6.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.5.7 Argentina

7.5.7.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.5.7.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.5.7.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.6 MEA

7.6.1 Market Size, By Country 2019-2026 (USD Billion)

7.6.2 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.6.3 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.6.4 Market Size, By End-Use, 2019-2026 (USD Billion)

7.6.5 Saudi Arabia

7.6.5.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.6.5.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.6.5.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.6.6 UAE

7.6.6.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.6.6.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.6.6.3 Market Size, By End-Use, 2019-2026 (USD Billion)

7.6.7 South Africa

7.6.7.1 Market Size, By Diagnosis, 2019-2026 (USD Billion)

7.6.7.2 Market Size, By Cancer Type, 2019-2026 (USD Billion)

7.6.7.3 Market Size, By End-Use, 2019-2026 (USD Billion)

Chapter 8 Company Landscape

8.1 Competitive Analysis, 2020

8.2 F. Hoffmann-La Roche Ltd.

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Strategic Positioning

8.2.4 Info-Graphic Analysis

8.3 GlaxoSmithKline PLC

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Strategic Positioning

8.3.4 Info-Graphic Analysis

8.4 Johnson & Johnson Services, Inc.

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Strategic Positioning

8.4.4 Info-Graphic Analysis

8.5 AstraZeneca PLC

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Strategic Positioning

8.5.4 Info-Graphic Analysis

8.6 Siemens Healthcare GmbH

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Strategic Positioning

8.6.4 Info-Graphic Analysis

8.7 Quest Diagnostics Incorporated

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Strategic Positioning

8.7.4 Info-Graphic Analysis

8.8 Thermo Fisher Scientific

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info-Graphic Analysis

8.9 Bio-Rad Technologies Inc

8.9.1 Company Overview

8.9.2 Financial Analysis

8.9.3 Strategic Positioning

8.9.4 Info-Graphic Analysis

8.10 Abbott Laboratories

8.9.1 Company Overview

8.9.2 Financial Analysis

8.9.3 Strategic Positioning

8.9.4 Info-Graphic Analysis

8.11 Pfizer Inc.

8.9.1 Company Overview

8.9.2 Financial Analysis

8.9.3 Strategic Positioning

8.9.4 Info-Graphic Analysis

8.12 Other Companies

8.12.1 Company Overview

8.12.2 Financial Analysis

8.12.3 Strategic Positioning

8.12.4 Info-Graphic Analysis

The Global Ovarian Cancer Diagnostics Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Ovarian Cancer Diagnostics Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global ovarian cancer diagnostics market?

The global ovarian cancer diagnostics market size is projected to grow from USD 25 billion in 2021 to USD 36.5 billion by 2026, at a CAGR of 7.5% during the forecast period.

Who are the major vendors in the ovarian cancer diagnostics market?

Key and innovative vendors in the ovarian cancer diagnostics market include F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca plc., Siemens Healthcare GmbH, Quest Diagnostics Incorporated., Thermo Fisher Scientific, Bio-Rad Technologies Inc., Abbott.

Which region has the highest market share in the ovarian cancer diagnostics market?

North America is estimated to hold the highest market share in the ovarian cancer diagnostics market.

What is the Covid-19 impact on future ovarian cancer diagnostics manufacturers?

Globally, Covid-19 impact on the future ovarian cancer diagnostics market will be quite significant for the manufacturers. North America would be leading because of the increasing investments in advanced imaging machines. Subsequently, the Asia Pacific market will be growing the fastest because of the increasing healthcare expenditure, and growing patient awareness.

What are the major drivers in the ovarian cancer diagnostics market?

The major driving factors for the ovarian cancer diagnostics market include the rising prevalence of ovarian cancer; the burgeoning proportion of chronic disorders related to the reproductive organ; increasing technological advancements in cancer diagnosis; soaring patient awareness regarding pre-disease diagnosis and other health concerns; easy availability of diagnostic medical devices in developing regions; rising geriatric women population; increasing studies on novel approaches in the ovarian cancer treatment.